Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cabozantinib in relapsed osteosarcoma and Ewing sarcoma
2014-004407-71Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in osteosarcoma (OS) and Ewing sarcoma (2 cohorts), sponsored by Institut Bergonié. Primary endpoints: 6-month non-progression rate, Composite primary endpoint for osteosarcoma and 1 more. Started Jan 2015; status: completed.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on 2014-004407-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004407-71.